NOVOS (NOVOS Age)

Overview

NOVOS (NOVOS Age) is the best price-to-depth ratio specialist in blood-based epigenetic bio-age testing — manufactured by NOVOS Labs (founded 2018 in NYC, Public Benefit Corporation), with structural value claim built on DunedinPACE clock + 11 organ ages + ~900,000 CpG sites at $349 pricing. The structural positioning is TruDiagnostic-equivalent depth at meaningfully lower price — close to TruDiagnostic’s 950k CpGs (only 50k difference) at $349 vs TruDiagnostic’s $399-799.

The structural value claim is genuine within the value-tier blood-based positioning: ~900,000 CpG sites analyzed via blood finger-prick collection, 3rd-generation DunedinPACE clock + organ age algorithms, 4 key results (biological age + rate of aging + 11 organ ages + telomere length) provide comprehensive multi-dimensional bio-age view. 55-page personalized longevity blueprint report delivers actionable recommendations beyond TruDiagnostic’s 85-page report at higher price. Free ENABL Age AI clock (photo-based estimate) provides entry-level accessibility before committing to paid test. Public Benefit Corporation ethos appeals to mission-aligned buyers.

The structural editorial caveats: slightly less resolution than TruDiagnostic (900k vs 950k CpGs — meaningful but small differential), smaller brand awareness than TruDiagnostic or Elysium, 4-week turnaround matches TruDiagnostic but lags InsideTracker InnerAge’s 3-5 days, supplement cross-selling (NOVOS Core / Boost products) may feel like upselling, and limited independent Trustpilot / review presence. For users matched to value-tier blood-based epigenetic positioning with DunedinPACE preference, NOVOS Age is structurally appropriate. For users wanting maximum resolution (TruDiagnostic 950k), strongest brand recognition (TruDiagnostic), or non-supplement-affiliated brand, alternatives are structurally better.

When NOVOS Age Makes Sense

Strong fit: Best price-to-depth ratio priority; DunedinPACE 3rd-generation clock preference; users wanting 11 organ ages + telomere length comprehensive view; Public Benefit Corporation ethos alignment; supplement-savvy biohackers in NOVOS ecosystem.

Weaker fit: Maximum resolution preference (TruDiagnostic 950k); strongest brand recognition (TruDiagnostic, Elysium); fastest turnaround (InsideTracker 3-5 days); supplement-cross-selling-averse buyers; minimalist single-number result preference (myDNAge).

3-Year Cost of Ownership

Compare: TruDiagnostic ($399-799), Elysium Index ($299), GlycanAge ($348), Tally Health ($229), Generation Lab ($490-500), MyDNAge ($299), Viome ($129-399 multi-omic).

Verdict: Recommended

NOVOS (NOVOS Age) earns a recommended verdict on the strength of its best price-to-depth ratio in blood-based epigenetic category (~900,000 CpGs + DunedinPACE + 11 organ ages at $349 — close to TruDiagnostic’s 950k depth at meaningfully lower price), 4 key results comprehensive multi-dimensional bio-age view (biological age + rate of aging + 11 organ ages + telomere length), 55-page personalized longevity blueprint report, free ENABL Age AI clock entry-level tool, Public Benefit Corporation ethos, and at-home finger-prick collection.

For value-priority blood-based epigenetic users wanting DunedinPACE 3rd-generation methodology + 11 organ ages at $349, NOVOS Age is structurally the leading consumer choice. For maximum resolution (TruDiagnostic), strongest brand recognition, fastest turnaround, or supplement-cross-selling-averse positioning, alternatives are structurally better matched.

Changelog

• 2026-05-07: Initial review published based on NOVOS (NOVOS Age) published specifications, DunedinPACE methodology positioning, Public Benefit Corporation ethos, ENABL Age AI tool documentation, and aggregated user-report data.